Category: Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis

Ceritinib is a brand new, oral, potent and selective second-generation anaplastic lymphoma kinase (ALK) inhibitor permitted by the Food and Drug Administration of the United

Read More